StemCell Therapy

Wall Street brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post earnings of $0.04 per share for the current quarter, according to Zacks. Three analysts have issued estimates for Crispr Therapeutics earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. Crispr Therapeutics reported earnings per share of ($0.92) in the same quarter last year, which suggests a positive year-over-year growth rate of 104.3%. The business is scheduled to report its next quarterly earnings results on Monday, February 24th.

On average, analysts expect that Crispr Therapeutics will report full year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.58 to $0.71. For the next fiscal year, analysts expect that the company will post earnings of ($4.72) per share, with EPS estimates ranging from ($5.76) to ($3.67). Zacks EPS averages are a mean average based on a survey of research firms that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to analysts expectations of $6.32 million.

CRSP has been the topic of a number of recent research reports. Piper Jaffray Companies reiterated an overweight rating on shares of Crispr Therapeutics in a report on Monday, October 21st. Needham & Company LLC reiterated a buy rating and issued a $62.00 target price on shares of Crispr Therapeutics in a report on Wednesday, July 31st. TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Canaccord Genuity initiated coverage on Crispr Therapeutics in a report on Friday, July 26th. They issued a buy rating and a $72.00 target price on the stock. Finally, Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a report on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the companys stock. Crispr Therapeutics has a consensus rating of Buy and a consensus target price of $57.95.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firms stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 21.40% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the business. Nikko Asset Management Americas Inc. lifted its stake in Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the companys stock valued at $113,846,000 after acquiring an additional 906,006 shares in the last quarter. ARK Investment Management LLC increased its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the companys stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the companys stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the companys stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Crispr Therapeutics by 6.1% during the 2nd quarter. Morgan Stanley now owns 284,984 shares of the companys stock valued at $13,423,000 after purchasing an additional 16,361 shares during the last quarter. Institutional investors and hedge funds own 51.09% of the companys stock.

Shares of CRSP traded up $2.67 during trading hours on Friday, reaching $53.58. The stock had a trading volume of 1,632,533 shares, compared to its average volume of 619,587. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $56.16. The firm has a 50-day simple moving average of $42.62 and a 200 day simple moving average of $44.25. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of -15.58 and a beta of 3.15.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Net Income

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Read the rest here:
$0.04 EPS Expected for Crispr Therapeutics AG (NASDAQ:CRSP) This Quarter - Casper Courier

This entry was posted on November 13, 2019 at 6:51 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |